RFL - Cornerstone Pharmaceuticals posts positive preclinical data from cancer drug trial

Cornerstone Pharma formerly known as Rafael Pharma (NYSE:RFL) is trading 5% higher after announcing positive preclinical data testing CPI-613 (devimistat) to target carcinoma catabolism. The study showed that devimistat suppressed the tricarboxylic acid hub, indispensable to many metabolic pathways, revealing that the drug substantially reduces the effective redundancy of tumor catabolism. The company said devimistat also showed occasional strong single agent activity against relapsed, refractory, Myc-driven Burkitt lymphoma in ongoing clinical trials. "Devimistat has the potential to bring new hope for remission and survival for patients suffering from rare cancers and serve as a chance to fill the substantial gap in treatment," said Sanjeev Luther, CEO of Cornerstone Pharma. In May, the European Medicines Agency granted orphan drug designation to CPI-613 to treat advanced unresectable biliary tract cancer.

For further details see:

Cornerstone Pharmaceuticals posts positive preclinical data from cancer drug trial